Biocompatibility of Plasma-Treated Polymeric Implants

Area of Science:

• Biomaterials science
• Cardiovascular research
• Medical device engineering

Background:

• Cardiovascular diseases are a leading cause of mortality globally.
• Artificial vascular grafts are essential for late-stage disease treatment, but current polymer materials have suboptimal properties.
• Small-diameter grafts (<6 mm) are particularly problematic due to increased platelet adhesion and thrombus formation.

Purpose of the Study:

• To review promising methods for improving the hemocompatibility of synthetic vascular graft materials.
• To explore hypotheses explaining enhanced hemocompatibility after plasma treatment.
• To highlight the lack of standardized hemocompatibility testing methods for biomaterials.

Main Methods:

• Literature review of methods to enhance biomaterial biocompatibility.
• Analysis of plasma treatment as a method to improve synthetic material hemocompatibility.
• Investigation of endothelialization using Human Umbilical Vein Endothelial cells.

Main Results:

• Platelet adhesion to synthetic materials is significantly influenced by adsorbed blood plasma proteins, especially fibrinogen.
• Plasma treatment is a promising method for improving the hemocompatibility of synthetic materials.
• Endothelialization with Human Umbilical Vein Endothelial cells can create a uniform cell layer, enhancing biocompatibility.

Conclusions:

• Standardized methods for testing biomaterial hemocompatibility are lacking despite numerous studies.
• Plasma treatment offers a promising approach to improve the hemocompatibility of synthetic vascular grafts.
• Further research is needed to understand and standardize hemocompatibility enhancement techniques for artificial grafts.